NASDAQ:ODT - Odonate Therapeutics Stock Price, Forecast & News

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.88) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.07) by $0.19. View Odonate Therapeutics' Earnings History.

Odonate Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Odonate Therapeutics.

2 Wall Street analysts have issued twelve-month target prices for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $26.00. On average, they expect Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 9.4%. View Analyst Price Targets for Odonate Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Odonate Therapeutics.

Headlines about ODT stock have trended very negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Odonate Therapeutics earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Odonate Therapeutics.

Some companies that are related to Odonate Therapeutics include Taro Pharmaceutical Industries (TARO), PTC Therapeutics (PTCT), Axsome Therapeutics (AXSM), Agios Pharmaceuticals (AGIO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Zai Lab (ZLAB), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Zogenix (ZGNX), ArQule (ARQL) and Epizyme (EPZM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Five Prime Therapeutics (FPRX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Bausch Health Companies (BHC) and Acorda Therapeutics (ACOR).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $28.71.

Odonate Therapeutics has a market capitalization of $921.13 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.

The official website for Odonate Therapeutics is http://www.odonate.com/.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]